The content on this site is intended for healthcare professionals only
Noam Shabani PA-C speaks to ecancer about what physician assistants need to know about PARP inhibitors in metastatic prostate cancer.
He explains which patients are suitable for treating with PARP inhibitors and how they compare to other treatment options.
Noam concludes by saying that research is still underway that can help inform what role PARP inhibitors play in the treatment of advanced prostate cancer.
This programme has been supported by an unrestricted educational grant from Pfizer.
Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC
Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance
KIM-1 is a good prognostic and predictive biomarker in advanced renal cell carcinoma
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Understanding the use of PARPi combinations to treat patients with mCRPC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Durable responses in aRCC, how do we optimise treatment?
EAU 2024: Bladder cancer latest
